Developing switchable bispecific T-cell engagers to fight cancer Who we are We are an immuno-oncology company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives. LEARN MORE Our technology Our pioneering...
Yes, Soteria Biotherapeutics is active; its latest activity on Parsers VC dates from May 17, 2021.
We use cookies to keep you signed in, remember your preferences and measure how the site is used. By continuing to browse Parsers VC you agree to that. Privacy & Terms
How would you rate Parsers VC?
On a scale from 1 to 10, how would you rate Parsers VC overall? It takes one click and helps us decide what to improve.
1 – poor10 – excellent
Thank you!
Your rating helps us make Parsers VC better.
Your rating was not saved
Something went wrong on our side. We will ask you again on one of your next visits.
Enjoying Parsers VC?
Thank you for rating Parsers VC so highly. Would you share your experience on G2? A short review helps other investors and founders find us.